Fox Chase Cancer Center News

PHILADELPHIA, PA (November 15, 2012)—Fox Chase Cancer Center’s Board of Associates—a long standing group of volunteers who raise money for research and patient care through special projects and fundraising events—was named Outstanding Volunteer Fundraising Group of the Year by the Association of Fundraising Professionals-Greater Philadelphia Chapter (AFP-GPC). The group was honored at AFP-GPC’s annual event at The Philadelphia Loews Hotel for National Philanthropy Day on November 14, 2012.

PHILADELPHIA, PA (November 12, 2012)—Pramod Krishnamurthy, MD, MPH, has joined Fox Chase Cancer Cancer’s pulmonary division within the department of medicine after completing a fellowship in interventional pulmonology at Henry Ford Hospital in Detroit, Mich. He has special interests in interventional pulmonology and its application in the diagnosis, staging, and treatment of lung and other cancers of the chest.

(Philadelphia, PA, November 8, 2012) – Larry Kaiser, MD, FACS, President and CEO of the Temple University Health System, has been named a “CEO of the Year” at the 2012 Healthcare Innovation Awards, sponsored by the Philadelphia Business Journal. Dr. Kaiser was among three area healthcare CEOs who accepted their awards at a breakfast ceremony on Thursday, November 8, at the Sheraton Hotel in Philadelphia, PA.  

PHILADELPHIA (November 5, 2012)—Fox Chase Cancer Center invites lung cancer patients and their caregivers to a FREE event titled “Together Facing Lung Cancer” on Monday, November 12, 2012 at 5:00 p.m. (dinner will be served at 5:00 p.m. and official program will start at 5:45 p.m.). The event, which offers support to patients and caregivers facing lung cancer, will be held in the Fox Chase Cancer Center auditorium (333 Cottman Avenue, Philadelphia).

PHILADELPHIA, PA (November 1, 2012)— Fox Chase Cancer Center is the first center in Pennsylvania to offer the newly U.S. Food and Drug Administration (FDA) approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.  

BOSTON, MA (October 31, 2012)—A routine blood test may help predict survival in patients with an aggressive form of skin cancer known as Merkel cell carcinoma, according to new findings by Fox Chase Cancer Center researchers. The results will be presented on Wednesday, October 31 at the American Society for Radiation Oncology’s 54th Annual Meeting.

BOSTON, MA (October 28, 2012)—Rectal cancer is more likely to spread to the lymph nodes in younger patients, according to new findings that Fox Chase Cancer Center researchers will be presenting on October 29 at the American Society for Radiation Oncology’s 54th Annual Meeting. The results—which are the first of their kind—suggest that doctors should search for spreading more aggressively in these patients.

BOSTON, MA (October 28, 2012)—Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy.